Establishment of Novel Prostate Cancer Risk Subtypes and A Twelve-Gene Prognostic Model

Prostate cancer (PCa) is the most common malignancy among men worldwide. However, its complex heterogeneity makes treatment challenging. In this study, we aimed to identify PCa subtypes and a gene signature associated with PCa prognosis. In particular, nine PCa-related pathways were evaluated in patients with PCa by a single-sample gene set enrichment analysis (ssGSEA) and an unsupervised clustering analysis (i.e., consensus clustering). We identified three subtypes with differences in prognosis (Risk_H, Risk_M, and Risk_L). Differences in the proliferation status, frequencies of known subtypes, tumor purity, immune cell composition, and genomic and transcriptomic profiles among the three subtypes were explored based on The Cancer Genome Atlas database. Our results clearly revealed that the Risk_H subtype was associated with the worst prognosis. By a weighted correlation network analysis of genes related to the Risk_H subtype and least absolute shrinkage and selection operator, we developed a 12-gene risk-predicting model. We further validated its accuracy using three public datasets. Effective drugs for high-risk patients identified using the model were predicted. The novel PCa subtypes and prognostic model developed in this study may improve clinical decision-making.

RhoBTB2 (DBC2) functions as a multifunctional tumor suppressor in thyroid cancer cells via mitochondrial apoptotic pathway

Thyroid cancer is the most common endocrine malignancy worldwide. Tumor suppressor gene RhoBTB2 (also known as Deleted in Breast Cancer 2, DBC2) was observed in various carcinomas, however, no reports showed the effects of RhoBTB2 on thyroid cancer. In our study, we found that RhoBTB2 decreases proliferation, increases apoptosis, inhibits mobility, and induces mitochondria damage in SW579 cells through increased Bax and decreased Bcl-2 and Bcl-xL protein expression. The effects of RhoBTB2 on SW579 cells were inversed by using butin (an inhibitor of the mitochondrial apoptosis pathway). Our results suggest that RhoBTB2 suppresses the growth of SW579 cells through a mitochondrial apoptosis pathway.